Our advanced kinase
inhibitors are designed
to address the key
limitations of cancer
therapies.
 
Press Releases

2017

April 03, 2017
Translational Research Results Confirm The Broad Activity of DCC-2618 in GIST Patients With Difficult to Treat Drug Resistant KIT Mutations

March 16, 2017
Deciphera Pharmaceuticals to Present at 27th Annual Oppenheimer Healthcare Conference

March 07, 2017
Deciphera Pharmaceuticals to Report Translational Research Findings with DCC-2618 at the 2017 American Association for Cancer Research (AACR) Annual Meeting

March 06, 2017
Deciphera Pharmaceuticals Initiates a Phase 1 Clinical Trial of DCC-3014

January 03, 2017
Deciphera Pharmaceuticals to Present at 35th Annual J.P. Morgan Healthcare Conference

2016

December 01, 2016
Deciphera Pharmaceuticals Reports Encouraging Clinical Results with DCC-2618 in Genetically-defined Cancers with Drug Resistant Mutations

October 31, 2016
Deciphera Pharmaceuticals to Present Clinical Data on Tumor Targeted Advanced Kinase Inhibitors at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 06, 2016
Deciphera Pharmaceuticals Appoints Christopher J. Morl, M.B.A. as Chief Business Officer

October 06, 2016
Deciphera Pharmaceuticals Expands Board with Appointment of Two New Directors

August 01, 2016
Deciphera Pharmaceuticals to Present at the Canaccord Genuity 36th Annual Growth Conference

June 16, 2016
Deciphera Pharmaceuticals to Present at JMP Securities Life Sciences Conference

April 20, 2016
Deciphera’s Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, Demonstrates Potent Macrophage Checkpoint Inhibition as a Single Agent and In Combination with an Anti-PD1 Inhibitor

March 21, 2016
Deciphera Pharmaceuticals Announces Study Results for Altiratinib Demonstrating Inhibition of Tumor Growth and Invasiveness in Glioblastoma

March 17, 2016
Deciphera Pharmaceuticals to Present Data on its Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, at American Association for Cancer Research Annual Meeting 2016

March 09, 2016
Deciphera Pharmaceuticals to Present at American Chemical Society Annual Meeting

February 29, 2016
Deciphera Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference

January 05, 2016
Deciphera Pharmaceuticals Increases Size of Series B Financing to over $90 Million with Addition of SV Life Sciences

2015

December 01, 2015
Deciphera Pharmaceuticals to Present at Oppenheimer Annual Healthcare Conference

November 23, 2015
Deciphera Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

September 21, 2015
Deciphera Pharmaceuticals Announces $75 Million Series B Financing to Advance Novel Oncology Pipeline

August 18, 2015
Deciphera Pharmaceuticals Announces Study Results for Altiratinib Demonstrating Inhibition of Three Major Cancer-Promoting Pathways to Durably Block Tumor Growth and Invasion

June 23, 2015
Top Medical Oncologists Join Deciphera Pharmaceuticals Scientific Advisory Board

June 19, 2015
Deciphera Pharmaceuticals to Present at JMP Securities Life Sciences Conference

April 22, 2015
Deciphera Pharmaceuticals Presents Data Highlighting Kinase Inhibitor Pipeline including Proprietary and Partnered Programs at AACR 2015 Annual Meeting

April 01, 2015
Deciphera Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference

March 23, 2015
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Private Company Conference Series

March 18, 2015
Deciphera to Present Data on Oncology Pipeline at American Association for Cancer Research Annual Meeting 2015

March 16, 2015
Deciphera Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference

March 16, 2015
Deciphera Pharmaceuticals Appoints Tucker Kelly as Chief Financial Officer

2014

November 20, 2014
Deciphera Pharmaceuticals Presents Data on Altiratinib (DCC-2701), an Advanced Multi-targeted Kinase Inhibitor, at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

November 17, 2014
Deciphera Pharmaceuticals Presents Data on Altiratinib (DCC-2701) that Demonstrated Inhibition of Tumor Growth and Invasion in Bevacizumab Resistant Glioblastoma

June 30, 2014
Deciphera Pharmaceuticals Appoints Oliver Rosen M.D. as Chief Medical Officer

May 30, 2014
Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for Altiratinib (DCC-2701) MET/TIE2/VEGFR/TRK Kinase Inhibitor for Solid Tumors

April 07, 2014
Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120 Pan-RAF Inhibitor Created and Developed in Collaboration with Eli Lilly

April 07, 2014
Deciphera Pharmaceuticals Appoints Michael D. Taylor, Ph.D., as President and Chief Executive Officer

March 17, 2014
Deciphera Pharmaceuticals Presents Preclinical Data on Rebastinib and DCC-3014 at AACR Tumor Microenvironment Conference

2013

August 05, 2013
Deciphera announces appointment of John de Groot, MD to its Scientific Advisory Board

July 27, 2013
Deciphera announces appointment of John Condeelis to its Scientific Advisory Board

2012

October 04, 2012
Deciphera Pharmaceuticals Announces Transition to an Oncology Drug Development Company

August 29, 2012
Deciphera Pharmaceuticals Announces Approval of rebastinib patent in Japan

June 11, 2012
Deciphera Pharmacueticals Announces Appointment of Kapil Bhalla, MD to its Scientific Advisory Board

April 26, 2012
Deciphera Pharmaceuticals Announces Appointment of Dr. Patrick O’Connor to its Scientific Advisory Board

February 01, 2012
Deciphera Pharmaceuticals Announces Collaboration Milestone with Eli Lilly and Company

2011

July 18, 2011
Kansas Biosciences Authority Votes in Favor of a $1.6MM Product Development Grant to Deciphera.

July 06, 2011
Deciphera Pharmaceuticals and the University of Kansas Cancer Center team up for clinical study of leukemia drug

April 18, 2011
Deciphera Pharmaceuticals Announces DCC-2036 research for CML published in Cancer Cell.

January 17, 2011
Deciphera Pharmaceuticals Announces Extension of BRAF collaboration and Receipt of Development Milestone from Eli Lilly and Company.

2009

April 07, 2009
Deciphera Pharmaceuticals announces initiation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and All

2008

October 03, 2008
KU to lease out vacant lab space for local expansion by Deciphera Pharmaceuticals

October 03, 2008
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement

Back to Top